Did you mean erenumab aloe and erenumab?
Displaying all 4 drugs
Erenumab
Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only...
Approved
Investigational
Matched Synonyms: … erenumab-aooe ... Erenumab …
Matched Name: … Erenumab …
Matched Description: … In particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity ... Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to ... Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the …
Matched Categories: … erenumab ... Amino Acids, Peptides, and Proteins …
Matched Name: … Erenumab …
Matched Description: … In particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity ... Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to ... Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the …
Matched Categories: … erenumab ... Amino Acids, Peptides, and Proteins …
Rimegepant
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] were the only CGRP antagonists ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and …
Ubrogepant
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years. ... [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and …
Fremanezumab
Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist...
Approved
Investigational
Matched Description: … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and ... [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. ... oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying all 4 drugs